Multiple Sclerosis Resource Centre

Welcome to the Multiple Sclerosis Resource Centre. This website is intended for international healthcare professionals with an interest in Multiple Sclerosis. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

GMSI Award 2016 – Merck’s commitment to MS and immunology

Steven Hildeman

This lecture was given at the Grant for Multiple Sclerosis Innovation Awards Event on September 15, 2016 in London. The GMSI award is sponsored by Merck KGaA, Darmstadt, Germany.

Merck’s commitment to MS research and treatment goes back over 20 years. In this session, Prof Hildemann reviews Merck’s 3-pronged approach to innovation, including promoting external innovation through the GMSI program, maintaining a focused R & D effort and developing patient support programs. Future goals include a better understanding of MS pathogenesis in the peripheral and central nervous system, more therapies, and a decrease in the monitoring burden patients currently experience. Areas of interest for future GMSI projects include a need to provide an earlier diagnosis of MS using sensitive surrogate markers, addressing therapy safety issues and lowering disease activity. GMSI aims to support MS in the areas of; the pathogenesis and prediction of MS subtypes, treatment response and markers of treatment response, potential new therapies, innovative patient-support programs, mobile health, devices, patient-reported outcomes, and other unmet needs such as individualised therapies.

Professor Steven Hildemann, Global Chief Medical Officer, Merck, Darmstadt, Germany